Week in Review: ChemPartner's Scientific Expertise

Published: Dec 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

December 28, 2013 --Dr. Arthur Taveras, President and CSO of ChemPartner, told ChinaBio® Today in an exclusive interview that the depth of ChemPartner’s scientific knowledge sets the CRO apart from its competition; Shenzhen Hepalink Pharma purchased Scientific Protein Laboratories, a US maker of heparin API, for $337.5 million; Walvax Biotech will acquire 64% of Shanghai’s Genor BioPharma, paying $49 million; Neurotron Biotechnology, a Hangzhou medical device company developing a cochlear implant, raised “as much as” $16.5 million in a C round; eight young children died in China after developing adverse reactions to a hepatitis B vaccine; TaiGen Biotech, a Taiwan-Beijing company, said the US FDA granted its lead antibiotic drug a five-year extension to the antibiotic’s exclusivity, priority review and fast track status. More details….

Stock Symbols: (SHE: 002399) (SHE: 300142)

Help employers find you! Check out all the jobs and post your resume.

Back to news